logo
Supply of life-saving medical products could be delayed by government freeze: 'This is a huge mess to untangle'

Supply of life-saving medical products could be delayed by government freeze: 'This is a huge mess to untangle'

Yahoo18-03-2025

The Trump administration's freeze of foreign aid has halted many people's access to crucial ongoing medications for HIV, malaria, and other high-risk diseases.
These problems are in line with what officials have said are unintended consequences of sweeping government freezes and cuts, though they remain unaddressed thus far.
Now, experts say that the consequences of the USAID freeze are disrupting the medical product supply chain and driving up prices for life-saving treatments.
As Reuters reported, USAID typically spends about $600 million annually on medicines, equipment, and diagnostic tests to help people in disadvantaged countries. However, the agency has now been cut off from spending, and there are far-reaching implications.
Medication and medical supply orders, which are usually made months in advance, are now on hold. Patients receiving continuous treatments can no longer receive necessary care.
Meanwhile, the global health supply chain is experiencing ripple effects from the foreign aid freeze. Experts say that a considerable backlog is already forming and that treatment prices will increase because of the order disruptions.
Fitsum Lakew Alemayehu, African Union liaison manager at WACI Health, told Reuters, "There will be a huge backlog. In Africa, millions have been on those treatments."
"This is a huge mess to untangle," said Health Response Alliance's CEO Tom Cotter.
The news of halted foreign aid for essential medical treatments is concerning in the short term and the long term. There will be immediate effects for the people who cannot continue with the treatments they started.
When you're choosing health and beauty products, which of these factors is most important to you?
Cost
Brand name
Ingredients
Packaging
Click your choice to see results and speak your mind.
Even if the funding freeze lasts only 90 days during a review period, as President Donald Trump initially indicated, production, delivery, and potentially legal issues will still need to be resolved before medicine and supply delivery can continue as in the past.
This news is also concerning because of the rise in vector-borne illnesses worldwide. Our planet's steady overheating is creating ideal conditions for mosquitoes to breed and thrive.
These insects are adapting to the rising temperatures, increasing the disease risks for people worldwide, especially in poor regions without access to readily available medications.
Companies that supply medical products are closely monitoring the halted foreign aid situation to help patients continue to gain access to the medications they depend on. Yet much is currently uncertain as HIV clinics close, emergency food aid halts, and research stops.
Given this uncertainty, communities must take preventative action to protect vulnerable people's health and curb our worsening climate conditions.
Although some diseases are unpreventable, there are simple actions individuals can take to protect themselves from other conditions.
For example, you can keep disease-carrying mosquitoes out of your yard and garden with naturally repelling plants like lavender and marigolds. Fortunately, there are many alternatives to toxic chemicals that you can use to keep mosquitoes away and reduce your disease risks.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

Yahoo

time2 hours ago

  • Yahoo

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment's impending Phase 2 data for pulmonary arterial hypertension. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of the trial, of 20%, which is regarded as a definite success. If the results are encouraging, TPIP may replace Tyvaso, the current standard treatment. On June 4, Wells Fargo reaffirmed its Buy recommendation, with a price objective of $107. Shi points out that TPIP's once-daily dosage is a significant benefit over Tyvaso's four-times-daily schedule, which could increase adherence and make it more appealing to patients as well as physicians. The efficacy potential of TPIP is supported by interim study results that show additional advantages in six-minute walk distance (6MWD). Shi expects significant market penetration in light of these considerations, which could lead to an increase in Insmed Incorporated (NASDAQ:INSM)'s valuation. Both analysts highlight that if future trial results live up to predictions, TPIP has the potential to completely change the way that PAHs are treated. Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm that improves the lives of individuals suffering from serious and rare diseases. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan

Yahoo

time2 hours ago

  • Yahoo

Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan

Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Biotech Stocks with Huge Upside Potential. Tessa Romero, an analyst at JPMorgan, has maintained her Overweight rating on Cytokinetics, Incorporated (NASDAQ:CYTK) but reduced the firm's price objective from $71 to $53. A lab technician using a microscope to examine the biopharmaceutical company's molecules. Aficamten's revised revenue projections, which anticipate a slower launch trajectory, are the basis for the modification. The management's latest remarks, which reflect the Camzyos launch pace for obstructive hypertrophic cardiomyopathy (oHCM), are consistent with this reevaluation. According to JPMorgan, expectations for adoption will be significantly influenced by the final medicine label. Cytokinetics, Incorporated (NASDAQ:CYTK) experimental treatment for oHCM, Aficamten, is still a valuable tool with promising clinical outcomes. Although JPMorgan admits that the launch trajectory was slower than anticipated, the company is still confident in the drug's unique profile when compared to Camzyos, especially with regard to pharmacology, safety, and dosing flexibility. These qualities and corroborating evidence support JPMorgan's assessment of aficamten's acceptability. The lower price objective is not a reflection of a shift in opinion about the drug's strategic worth or efficacy, but rather of modified commercial ramp assumptions. It is a late-stage biopharmaceutical business that focuses on discovering, developing, and bringing to market first-in-class muscle activators and next-in-class muscle inhibitors as possible cures for fatal diseases where muscle function is impaired or deteriorating. While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Fast Five Quiz: Diffuse Large B-Cell Lymphoma
Fast Five Quiz: Diffuse Large B-Cell Lymphoma

Medscape

time2 hours ago

  • Medscape

Fast Five Quiz: Diffuse Large B-Cell Lymphoma

Although diffuse large B-cell lymphoma (DLBCL) is characterized by aggressive clinical behavior, standard treatment can provide good long-term survival outcomes. However, management can be complex, with certain comorbidities exacerbating disease severity and complications such as extranodal involvement significantly affecting prognosis. Understanding the nuances of DLCBL presentation, diagnosis, and management is key to delivering the best outcomes to patients affected by this rapidly progressive disease. What do you know about DLBCL? Check your knowledge with this quick quiz. Both primary and secondary Sjögren syndrome are strongly associated DLBCL. Other autoimmune disorders that have been associated with DLBCL include hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease. In addition to autoimmune disorders, viral infections have also been linked to DLBCL; these include HIV, hepatitis B, hepatitis C, and Epstein-Barr. Further, data have shown that patients with rheumatic diseases have a heightened risk of DLBCL development. Though fugal or bacterial pneumonia, humoral deficiency, and bone infections (such as osteomyelitis) can occur in patients with DLBCL, data have indicated that survivors of DLBCL were more likely to experience these conditions, rather than being strongly linked to DLBCL itself. Learn more about DLBCL staging. In the NCCN's guidelines, PET/CT is the preferred modality for imaging in DLBCL workup. C/A/P CT with contrast can also be used in a complementary setting to help stage the disease and identify other factors such as extranodal disease or visceral involvement, but it is not preferred. Although not essential, head CT/MRI or neck CT/MRI with contrast (as well as bone marrow biopsy) can be useful for workup in selected cases. Specifically, bone marrow biopsy can be helpful in identifying indolent or low-volume disease. However, the NCCN notes that bone marrow biopsy is not needed if PET/CT shows bone disease. Learn more about DLBCL workup. Data indicate that extranodal involvement occurs in approximately 30%– 50% of patients with DLBCL; further, it is reported that gastrointestinal involvement is the most common extranodal site. Other affected sites include the skin, bones, spleen, and central nervous system; kidneys, testicles, and the liver can also be impacted, but they are not regarded as the most common. Learn more about DLCBL and extranodal involvement. A population-based study involving over 30,000 patients with extranodal DLBCL found that the best outcomes are associated with heart and mediastinal sites, with a 42% reduction in mortality risk compared with involvement of the intestinal tract. Involvement of the pancreas and hepatobiliary system, respiratory system, or nervous system are associated with significantly greater risks of mortality compared with the intestinal tract. Other factors associated with greater mortality risk include late age at onset, history of other malignancy, late age at presentation, and Black, non-Hispanic ethnicity. Learn more about DLBCL prognosis. CAR T therapy is typically utilized as a second-line treatment for patients with relapsed/refractory DLBCL. CD19-directed CAR T-cell therapy is considered ' the standard of care' for relapsed/refractory DLBCL, with three treatments approved for this population. Although a number of factors can lead to CAR T cell therapy resistance, the key mechanism is typically down regulation or loss of CD19 expression. Abnormal differentiation and dysfunction of T cells can also cause poor response to CAR T therapy, and being unable to collect enough T cells can also negatively affect the impact of CAR T products; however, these factors are not considered key mechanisms for resistance to CAR T-cell therapy. As such, early collection of T-cells in high-risk patients with DLBCL is one strategy to ensure enough T cells are available when needed. Partial response or relapse after CAR T therapy should prompt third-line therapy, such as alternative systemic therapy not previously given, clinical trial, palliative involved-site radiation therapy, or best supportive care. Learn more about relapsed or refractory DLBCL.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store